A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion — Masatoshi Kudo (2021) | RDL Network
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
achievement of marked tumor shrinkage," which differs from the treatment concept for other types of advanced cancer or advanced HCC.Upfront Systemic Therapy with Subsequent Locoregional Therapy/Resection in Intermediate-Stage HCC
Masatoshi Kudo, Kwang–Hyub Han, S.-L. Ye, Jianhua Zhou, Yi‐Hsiang Huang, Shi‐Ming Lin, Chien‐Kuo Wang, Masafumi Ikeda, Stephen L. Chan, Su Pin Choo, Shiro Miyayama, Ann‐Lii Cheng, On Behalf Of The APPLE Association
Discussion(0)
No comments yet. Be the first to comment.